Concourse Financial Group Securities, Inc. Ambrx Biopharma Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share
Q3 2023 Oct 30, 2023	BUY	$9.3 - $16.6 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$9.3 - $16.6 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$7.66 - $16.46 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.46 - $12.54 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.41 - $4.54 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.06 - $2.96 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$2.53 - $4.35 $0 - $0
Q1 2022 May 09, 2022	BUY	$4.07 - $9.0 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$8.11 - $13.91 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$13.31 - $22.53 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$15.95 - $19.6 $0 - $0

Others Institutions Holding AMAM

# of Institutions

Shares Held

31.2K

Call Options Held

Put Options Held

View Full List

About Ambrx Biopharma Inc.

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

More about AMAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account